car-t as a new standard of care in lymphoma
Published 2 years ago • 180 plays • Length 2:30Download video MP4
Download video MP3
Similar videos
-
8:50
an update of car t-cell therapies in lymphoma
-
4:02
the future of car-t and cellular therapy
-
1:56
the future of car t-cell therapies in hematologic malignancies
-
4:24
investigating production failure and out-of-specification production of car t-cell therapeutics
-
3:43
the future of car-t therapy
-
1:15
car t-cells in hematological malignancies
-
1:53
the impact of t-cell fitness on patient response to car-t therapy
-
4:43
immunotherapy & car t cells: part 1
-
11:17
car-t cells: engineered cancer killers
-
5:52
chimeric antigen receptor (car) / car-t
-
1:29
what is car t cell therapy?
-
2:30
the future of car t-cell therapy
-
3:01
phase 1 trial of car t-cell therapy for lymphoma
-
2:09
the financial burden of car t-cell therapy
-
2:14
exploring the potential role of cd7-targeting car-t cells for the treatment of t-all
-
1:35
key mechanisms of resistance to car t-cell therapy
-
3:10
universal car-t therapy for t-all
-
1:08
point-of-care car t-cells
-
1:08
car-t therapy: treatment burden and costs
-
2:48
outcomes of autosct, allosct & car-t cell therapy in patients with tp53-altered mcl
-
2:02
advances in off-the-shelf car t-cells
-
1:33
car t-cell therapy: on the way to success